Aortic & peripheral vascular diseaseCohort study
Lack of association between fluoroquinolone and aortic aneurysm or dissection
- Nationwide population-based cohort study with self-controlled case series
- inverse probability of treatment-weighted Cox model
Authors' conclusion
There was no significant difference in the risk of AA/AD in patients who were administered oral FQ compared to those administered 3GC.
Study context
- Population
- Adults aged ≥20 years prescribed oral fluoroquinolone (FQ) or 3GC at outpatient visits, 2005–2016, National Health Insurance Service database
- Participants
- 954,308 adults
- Exposure
- Oral FQ vs 3GC
- FQn = 777,109
- 3GCn = 177,199reference
- Outcome
- Hospitalization or in-hospital death with a primary diagnosis of AA/AD
Main finding
AA/AD
Adjusted hazard ratio
0.752
95% CI 0.515–1.100
By group
FQ vs 3GC
adjusted HR 0.752 (95% CI 0.515–1.100)
As reported in the abstract
Observational data: associations, not effects.
Further findings
Subgroup and sensitivity analyses
- Consistent results
Original publication
Lack of association between fluoroquinolone and aortic aneurysm or dissection. Eur Heart J. Published 19 September 2023. doi:10.1093/eurheartj/ehad627
Summarised from the published abstract; every number is checked against it